In July 2026, GP2 announced the 12th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PDRD. This release includes 21,156 additional genotyped participants and 25,046 additional whole genome sequencing (WGS) participants. - The genotype array (NeuroBooster Array ) data, including locality-restricted samples, now consists of a total of 124,942 genotyped participants (64,228 PD cases, 34,925 Controls, and 25,789 “Other” phenotypes). - The WGS data now consists of a total of 63,272 sequenced participants (37,106 PD cases, 17,404 Controls, and 8,762 Other phenotypes). - The clinical exome data consists of 14,648 samples with PD. - Of the 147,451 unique samples with genetic data (NBA, WGS, or clinical exome), 53,869 individuals also have additional extended clinical information. Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.20932193, release 12) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org."